(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release
